University of Glasgow

Early Access Partnership with Dr. Nigel Jamieson to Explore 3D Spatial Biology in Oncology Research BOSTON, April 24, 2025 /PRNewswire/ -- Stellaromics, a pioneer in 3D spatial biology, today announced that Dr. Nigel Jamieson and his team at the University of Glasgow are the first European users of the company's Pyxa platform. As an inaugural early access partner, Dr. Jamieson, a physician-scientist and Professor at the University of Glasgow, will lead oncology-focused research using the platform. His team will apply Pyxa's 3D spatial multi-omics workflow to investigate tumor architecture and the surrounding microenvironment, with the goal of uncovering new cancer biomarkers that could inform pharmaceutical development and future clinical applications. Continue Reading Dr. Jamieson's lab, which also operates as a spatial biology core facility, is applying the full Pyxa workflow—from sample preparation and 3D spatial sequencing to data analysis—to generate high-resolution spatial maps of tumor samples. By visualizing tumors at sub-cellular resolution and analyzing thick tissue sections with integrated multi-omic data, the team aims to uncover cellular interactions and disease mechanisms with greater precision in clinically relevant contexts. It's about working with passionate researchers who are pushing the boundaries of what's possible in cancer science... Post this This collaboration marks a significant step forward for Stellaromics, underscoring Pyxa's growing role in oncology and translational research. The work at the University of Glasgow showcases the platform's potential to advance cancer diagnostics and therapeutics, aligning with Stellaromics' mission to enable precision medicine through true 3D spatial biology. "Partnering with Dr. Jamieson and the University of Glasgow as our first site in Europe is an exciting step forward for us," said Todd Dickinson, Ph.D., CEO of Stellaromics. "It's more than just expanding our footprint to Europe—it's about working with passionate researchers who are pushing the boundaries of what's possible in cancer science. We are thrilled to provide Dr. Jamieson and his colleagues with a powerful new tool in the fight against cancer." By capturing spatial gene expression data at sub-cellular resolution in thick tissue samples, Pyxa enables a comprehensive understanding of complex biological systems in three dimensions. This early access program will help inform how 3D spatial biology can advance cancer biomarker discovery, with the potential to inform future diagnostic and therapeutic strategies. "It's an exciting opportunity to be among the first to work with the Pyxa platform," said Dr. Nigel Jamieson. "Studying tumors in 3D gives us a much richer understanding of how cancer behaves in real tissue. The ability to analyze thicker sections and integrate multi-omic data opens new possibilities for discovering biomarkers and developing more precise therapies." The collaboration will be highlighted during a May 9 event in London, Next-Generation Cancer Diagnostics Grand Challenge, featuring leaders from the UK Department of Health, pharmaceutical companies, and spatial biology researchers . Stellaromics will continue to expand its early access program with additional instruments shipping in summer 2025. About Stellaromics Stellaromics is a privately held company dedicated to pioneering breakthroughs in 3D spatial multi-omics. The company's mission is to empower researchers with cutting-edge tools that illuminate the complexities of biological systems, enabling groundbreaking discoveries that improve human health. Stellaromics is headquartered in Boston, Massachusetts, USA. Media Contact Kristen White Co-Founder & Partner, Oak Street Communications [email protected] 415.608.6060 SOURCE Stellaromics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Collaboration Includes Houston-based Gene by Gene's Laboratory Expertise to Support Evidence Generation for Personalized Medicine HOUSTON, April 17, 2025 /PRNewswire/ -- The University of Glasgow's Living Laboratory for Precision Medicine and myDNA, a leader in precision health, have announced a new partnership to generate evidence supporting the adoption of pharmacogenomics (PGx) in healthcare. The collaboration will focus on exploring the potential of PGx to transform healthcare delivery, aiming to enhance patient outcomes through precision medicine. PGx works by tailoring drug choice and dosage to an individual's genetic profile, marking a significant shift away from the traditional "one-size-fits-all" model. As healthcare increasingly shifts towards more personalised solutions, PGx is gaining attention for its potential to address the complex and varied - and often detrimental - responses that patients can experience with certain medications. Through their partnership, the Living Laboratory for Precision Medicine, myDNA, Gene by Gene laboratory services and technology partner Agena Bioscience will focus on generating real-world data to assess the clinical benefits and cost-effectiveness of PGx. These insights will be instrumental in advocating for its broader adoption within the NHS and healthcare systems worldwide. The ultimate goal of this collaboration is to generate evidence that will drive the integration of personalised medicine as a standard practice in healthcare. In doing so, it aims to help improve medication safety and efficacy for patients and contribute to significant cost savings for healthcare systems. Professor Sandosh Padmanabhan, Pontecorvo Chair of Pharmacogenomics at the University of Glasgow, said: "Our partnership with myDNA marks the crucial first step in integrating pharmacogenomics into everyday clinical practice across Scotland. By combining the University of Glasgow's research expertise, myDNA's specialised knowledge in pharmacogenomics, and NHS Greater Glasgow and Clyde's capabilities in clinical trials, we are laying the groundwork for the wider adoption of personalised medicine within the NHS, with the goal of significantly enhancing patient care. "Additionally, the evidence we generate will not only benefit the NHS but also have far-reaching impact beyond the UK, supporting the global adoption of pharmacogenomic strategies." "Allan Sheffield, myDNA Co-founder, said, "myDNA is excited to partner with the University of Glasgow's Living Laboratory for Precision Medicine to accelerate pharmacogenomics adoption. Our expertise in providing pharmacogenomic clinical decision support, coupled with the Living Lab's research capabilities, positions us to generate compelling real-world evidence showcasing PGx's clinical and economic value." Dr Sam Mostafa, myDNA's Clinical Director and Pharmacogenomic Specialist said "This collaboration with the University of Glasgow's Living Laboratory for Precision Medicine is a pivotal moment in unlocking the potential of pharmacogenomics. By generating strong data, we can demonstrate how personalized medication management can significantly enhance patient safety and efficacy." About Gene by Gene: Gene by Gene is a world leader in genetic testing services with over 20 years of experience. Our laboratory holds accreditation from multiple agencies, including CAP, CLIA, New York State Department of Health, California Department of Public Health, and AABB. With a cutting-edge laboratory and highly trained team of experts, we are committed to excellence in the field of genetic analysis. To learn more about Gene by Gene, visit . Media Contact: Josie Zohny | Clarity Quest for Gene by Gene [email protected] 917-742-3777 SOURCE Gene by Gene WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Neuranics, a Scottish deep-tech semiconductor company, has secured $8 million in seed funding for its magnetic sensing technology. Blackfinch Ventures led the round, with participation from Archangels, Old College Capital, the University of Glasgow, Par Equity and the University of Edinburgh's venture investment fund. WHAT IT DOES Neuranics offers ultra-sensitive, low-power magnetic sensing technology that detects tiny signals from the human body to track muscle activity for gesture recognition and heart signals without touching the skin. The company's gesture recognition Tunneling Magnetoresistance (TMR) quantum sensing technology consists of custom semiconductor designs and AI-enabled hardware and software. Neuranics, founded in 2021, is a spin-out from the Universities of Glasgow and Edinburgh. The company will use the funds to accelerate its international growth and commercial adoption of its technology, expand its team, and enable the integration of its TMR technology into high-tech markets, such as digital health, extended reality (XR) and wearables. The company touts that it is actively collaborating with Tier-1 semiconductor and XR manufacturers to demonstrate its value and production readiness in industrial, consumer and healthcare markets. "The team at Neuranics have shown us that they can not only accurately detect finite movement but do so whilst consuming low power, which clearly opens up a tremendous number of applications across business and industry. Neuranics have an exciting market for their technology, and we look forward to working with the team," Kimberley Hay, senior ventures manager at Blackfinch Ventures, said in a statement. MARKET SNAPSHOT The funding comes less than six months after Neuranics garnered $700,000 in seed funding in a round led by Inflection Point Ventures. A month before, the company announced it secured an £800,000 ($1.03 million) grant from Scottish Enterprise. The grant aimed to support a £2.4 million ($3.11 million) project that uses magnetomyography (MMG) technology and machine learning to interpret muscle movements using wristbands. The project initially targeted XR applications, enabling gesture recognition and muscle activity monitoring using wristbands for natural gesture-based interactions in immersive environments. In 2023, the company garnered a $2.3 million investment led by Par Equity and announced the launch of a magnetic sensor development kit that records the magnetic activity of one's heart and transfers that information to a smartphone, tablet or laptop over Bluetooth for 24/7 recording and analysis.